Tarun katheriya | Stem Cell Research | Research Excellence Award

Published on by Cell Biologist

Dr. Tarun katheriya | Stem Cell Research | Research Excellence Award

IIT BHU Varanasi | India

Tarun Katheriya is a physicist with extensive expertise in the synthesis, characterization, and analysis of advanced functional materials, particularly negative-permittivity ceramics, perovskites, and multifunctional composites for electromagnetic interference (EMI) shielding and wearable electronics. His Ph.D. research focused on developing epsilon-negative materials, including layered perovskites and glass-ceramics, with tunable dielectric and conductive properties. He has synthesized a variety of electro-ceramics and glass-ceramics, exploring their dielectric behavior through classical and modified Drude models, and demonstrated their EMI shielding effectiveness. Notably, his work includes investigating coil-less inductive properties in conducting ceramics and studying the electrochemical performance of these materials. Katheriya has contributed to understanding the correlation between conductivity and permittivity in doped perovskites, as well as high-temperature dielectric properties in layered oxides. His research integrates experimental synthesis with theoretical modeling, advanced characterization techniques such as XRD, SEM, impedance analysis, and vector network analysis, and simulation tools including FullProf, Zview, and Gaussian. His published work highlights innovations in metal-free nanocomposites, negative-permittivity behavior, and multifunctional EMI shielding, positioning him at the forefront of materials development for next-generation electronic applications.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications: 

  1. Katheriya, T., Pandey, S., & Upadhyay, S. (2025). New frontiers in ceramic composites: Tunable electromagnetic interference shielding by realizing negative permittivity in SnO₂/LaNiO₃ nanocomposites. Journal of Materials Chemistry C.

  2. Katheriya, T., Nirala, G., & Upadhyay, S. (2025). Study of negative permittivity in nanosized LaNiO₃ for electromagnetic interference shielding: A modified Drude model approach. ACS Applied Electronic Materials.

  3. Katheriya, T., Nirala, G., & Upadhyay, S. (2024). Establishing the correlation of negative permittivity and AC conductivity of La₂₋ₓSrₓNiO₄ (x = 0, 0.1, 0.3, 1.0) for microwave shielding applications. Journal of Materials Chemistry C, 12(23), 8473–8484.

  4. Katheriya, T., & Upadhyay, S. (2023). High-temperature study of dielectric and electrical conduction behavior of La₂NiO₄. Physica Scripta, 98(10), 105969.

  5. Verma, H., Mittal, A., Kumar, P., Katheriya, T., Bhattacharya, B., & Upadhyay, S. (2025). Enhanced supercapacitor performance of rGO-modified LaFeO₃ perovskite: Experimental and DFT insights. Materials Chemistry and Physics, 131771.

  1. Nirala, G., Katheriya, T., Yadav, D., Verma, H., & Upadhyay, S. (2023). The evolution of coil-less inductive behavior in La-doped Sr₂MnO₄. Emergent Materials, 6(6), 1951–1962. https://doi.org/[DOI if available]Nirala, G., Yadav, D., Katheriya, T., & Upadhyay, S. (2022). Temperature-dependent negative permittivity in solid solutions Sr₂Mn₁₋ₓSnₓO₄ (x = 0, 0.3, 0.5). Journal of the European Ceramic Society, 42(2), 453–461.

  2. Nirala, G., Katheriya, T., Yadav, D., Pandey, S., & Upadhyay, S. (2022). Effect of Nb doping on epsilon negative behaviour of Sr₂MnO₄. Journal of Materials Science, 57(33), 15862–15875.

  3. Mishra, R. K., Avinashi, S. K., Kumari, S., Nain, R., Katheriya, T., Dwivedi, R. K., … Gautam, C. (2024). Synergistic doping effect of La₂O₃ on BaO–TiO₂–SiO₂ glass-ceramics: Evolution of physical, structural, morphological, and dielectric behaviour for electronics applications. Journal of Alloys and Compounds, 990, 174354.

Tong Ming Liu | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Tong Ming Liu |  Stem Cell Research | Best Researcher Award

Institute of Molecular and Cell Biology | Singapore

Dr. Tong Ming Liu’s research focuses on advancing gene and cell therapy through innovative studies on human mesenchymal stem cells (hMSCs) and induced pluripotent stem cells (iPSCs). His work explores the mechanisms governing mesenchymal stem cell stemness, potency, and ageing, with the goal of improving the therapeutic efficacy and manufacturing quality of MSC-based treatments. A central aspect of his research is identifying and characterizing critical quality attributes (CQAs) in MSC manufacturing to ensure consistent and safe clinical applications. Dr. Liu also investigates disease modeling of bone and cartilage disorders using iPSC-derived MSCs to facilitate drug screening and gene correction strategies. His recent projects include the development of optimized media for iPSC, iPSC-MSC, and MSC culture, as well as identifying novel biomarkers to select high-quality MSCs for regenerative medicine. Through his studies, he aims to enhance the scalability, functionality, and translational potential of stem cell therapies. His findings have been recognized in scientific forums such as the EVANTICA Symposium and Singapore Cell and Gene Therapy Conference, underscoring his contribution to the development of efficient MSC-derived extracellular vesicle (MSC-EV) optimization and regenerative therapy innovations.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Liu, T. M.*, Tew, W., Yang, Z., Lim, B., Hui, J. H. P., Lee, E. H., Loh, Y.-H., & Cool, S. (2025). Understanding the molecular basis of mesenchymal stem cell stemness: Implications for clinical applications. Cell Death & Disease, 16(1), 778.

Liu, T. M.* (2025). MSC-EVs: Pioneering the next generation of biomedical applications. World Journal of Stem Cells, 17(6), 108197.

Liu, T. M.*, & Wu, Y. (2023). Advancing gene and cell therapy using human mesenchymal stem cells. Frontiers in Cell and Developmental Biology, 11, 1294460.

Shou, Y., Liu, L., Le, Z., Lee, K. L., Li, X., Koh, D. Z., Wang, Y., Liu, T. M., Yang, Z., Lim, C. T., Cheung, C., & Tay, A. (2023). Mechano-responsive hydrogel for directing stem cell manufacturing and therapy. Bioactive Materials, 24, 387–400.

Liu, T. M.* (2021). Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World Journal of Stem Cells, 13(12), 1826–1844.

Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., Ng, S. K., Yang, Y. S., Lezhava, A., Hui, J., Oh, S., & Cool, S. M. (2022). Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy, 24(5), 456–472.

Liu, T. M.*, Yildirim, E. D., Li, P., Fang, H. T., Denslin, V., Kumar, V., Loh, Y.-H., Lee, E. H., Cool, S. M., Teh, B. T., Hui, J. H., Lim, B., & Shyh-Chang, N. (2020). Ascorbate and iron are required for the specification and long-term self-renewal of human skeletal mesenchymal stromal cells. Stem Cell Reports, 14(2), 210–225.

Arzu Yay | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Arzu Yay | Stem Cell Research | Best Researcher Award

Erciyes University | Turkey

Prof. Arzu Yay is a distinguished researcher in the Department of Histology and Embryology at Erciyes University, Turkey. Her work focuses on cellular and molecular mechanisms underlying tissue development, injury, and repair, with emphasis on immunohistochemical and ultrastructural analyses. Her M.Sc. research examined E-cadherin expression during renal development in the prenatal period, contributing to the understanding of epithelial differentiation in organogenesis. Her Ph.D. focused on nestin expression across different grades of meningiomas and glioblastomas, highlighting neural stem cell marker dynamics in tumor progression. She has conducted significant studies on oxidative stress, neurobiology, and tissue damage, including investigations into the effects of melatonin and vitamin C on alcohol-induced lung injury and nitric oxide synthase immunoreactivity. Her research has also explored tissue-level alterations in diabetes and the histological impacts of hormonal and anesthetic agents. Prof. Yay’s postdoctoral work at the University of Lübeck, Germany, further advanced her expertise in dermatological histopathology. Her contributions have been recognized through multiple national and international awards for excellence in experimental and translational research, particularly in antioxidant mechanisms and radioprotection. Her body of work reflects a strong integration of histological, molecular, and ultrastructural approaches in biomedical sciences.

Profiles: Google Scholar | Scopus

Featured Publications:

Yıldız, K., Efesoy, S. N., Ozdamar, S., Yay, A., Bicer, C., Aksu, R., & Kılıc, E. (2011). Myotoxic effects of levobupivacaine, bupivacaine and ropivacaine in a rat model. Clinical Investigation in Medicine, 34(5), 273–280.

Sarıozkan, S., Bucak, M. N., Canturk, F., Ozdamar, S., Yay, A., Tuncer, P. B., Ozcan, S., Sorgucu, N., & Caner, Y. (2012). The effects of different sugars on motility, morphology and DNA damage during the liquid storage of rat epididymal sperm at 4°C. Cryobiology, 65(2), 93–97.

Sarıozkan, S., Canturk, F., Yay, A., & Akçay, A. (2012). The effect of different storage temperature on sperm parameters and DNA damage in liquid stored New Zealand rabbit spermatozoa. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 18(3), 475–480.*

Yay, A., Ozdamar, S., Canoz, O., Tucer, B., & Baran, M. (2013). Nestin expression in meningiomas of different grades. Journal of Neurological Sciences (Turkish), 30, 532–540.

Sarıozkan, S., Türk, G., Canturk, F., Yay, A., Eken, A., & Akçay, A. (2013). The effect of bovine serum albumin and fetal calf serum on sperm quality, DNA fragmentation and lipid peroxidation of liquid stored rabbit semen. Cryobiology, 67(1), 1–6.*

Ernst, N., Yay, A., Bíró, T., Tiede, S., Humphries, M., Paus, R., & Kloepper, J. E. (2013). β1 integrin signaling maintains human epithelial progenitor cell survival in situ and controls proliferation, apoptosis and migration of their progeny. PLoS ONE, 8(12), e84356.*

Yay, A., Ozdamar, S., Canoz, O., Baran, M., Tucer, B., & Sonmez, M. F. (2014). Intermediate filament protein nestin is expressed in developing meninges. Bratislava Medical Journal, 115(11), 718–722.*

Hossein Abdizadeh | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Hossein Abdizadeh | Tissue Engineering Regeneration | Best Researcher Award

University of Tehran | Iran

Hossein Abdizadeh is a leading researcher in the field of materials engineering, specializing in the synthesis of nano-materials, semiconductors, and nano-structured composites. His research emphasizes the fabrication, characterization, and functional optimization of advanced ceramic and composite materials. His doctoral work focused on the development and analysis of duplex alumina-based three-layer laminated composites, exploring their structural and mechanical properties. He also investigated surface hydroxyl groups in ceramic materials using infrared spectrometry during his postgraduate studies, contributing to a deeper understanding of surface chemistry in ceramics. Over his career, he has led multiple university and industry-collaborative research projects, advancing applications of nano-structured materials in engineering contexts. Abdizadeh has a prolific publication record, with over 156 papers in international journals, numerous national and international conference contributions, and a Farsi-language book on chemical methods for producing nanoparticles. In 2009, he established the Nano-structured Materials and Composites Laboratory at the University of Tehran, fostering experimental research in advanced composites, nanomaterials, and their applications in metallurgy and materials science. His work combines experimental synthesis, microstructural characterization, and the study of material properties to develop innovative solutions in materials engineering and nanotechnology.

Profiles: Google Scholar | Scopus

Featured Publications:

Abdizadeh, H., Ghelich, R., Farhangian, M., Akbari Asbagh, R., Ahmadi Tafti, S. M., Foroutani, L., Chehresonboll, Y., & Poopak, A. (2025). Bioactive chitosan/polycaprolactone cryogel sponge co-loaded with ciprofloxacin and ginger for controlled drug release and healing of infected wounds. Materials & Design.

Abdizadeh, H., Khodabandeh, F., & Golobostanfard, M. R. (2025). Decoration of ZnO nanorod arrays with heterojunction of graphene quantum dots and MoS2 nanoparticles for photoelectrochemical water splitting. Applied Energy Materials.

Abdizadeh, H., Bakhshaei, P., & Ataie, A. (2024). Facile mechanical fabrication of Cu-Ni/CNT nanocomposite for improved microstructural, hardness, and electrical characteristics. Institute of Materials, Minerals & Mining.

Abdizadeh, H., Khodabandeh, F., Abdollahi Avanaki, A., & Golobostanfard, M. R. (2024). Photoelectrochemical water splitting based on chalcopyrite semiconductors: A review. International Journal of Hydrogen Energy, 65, 779–803.

Abdizadeh, H., Ghorbani, M., Sheibani, S., & Golobostanfard, M. R. (2024). Efficient synthesis of recyclable porous BiFeO3/rGO thin film via sol-gel method as an enhanced photocatalyst. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 686, 133429.

Abdizadeh, H., Beighi, M., Pourabdoli, M., & Raygan, Sh. (2023). Direct synthesis of tungsten carbide by solid‑state carbothermic reduction of tungsten trioxide. Transactions of the Indian Institute of Metals, 76(12), 3455–3461.

Kelly Bosak | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Kelly Bosak | Stem Cell Research | Best Researcher Award

University of Kansas Medical Center | United States

Dr. Kelly A. Bosak, PhD, APRN, ANP-BC, FHFSA, is a tenured Associate Professor at the University of Kansas Medical Center and a nationally recognized expert in heart failure care, nursing science, and implementation research. With a strong background in advanced practice nursing and nursing administration, Dr. Bosak has made significant contributions to interdisciplinary research focused on improving clinical outcomes in cardiology, rural health, and chronic disease management. Her peer-reviewed work spans high-impact journals such as The Journal of Cardiac Failure, Implementation Science, and The Journal for Nurse Practitioners, reflecting her leadership in both clinical practice and academic scholarship. Dr. Bosak has authored or co-authored over 30 peer-reviewed publications, with a Scopus h-index of 10, over 450 citations, and 32 documents indexed in major databases. She has played a pivotal role in national reports from the Heart Failure Society of America and led multiple implementation science projects aimed at integrating evidence-based interventions into routine care. Her current research emphasizes digital health innovation and workforce development in underserved communities. Dr. Bosak’s interdisciplinary collaborations and translational research continue to shape evidence-based practice and policy in cardiovascular nursing and advanced practice nursing education.

Profiles: Google Scholar | Scopus

Featured Publications:

  • “Return on Investment of a Nurse Practitioner Fellowship Program”

  • “Interprofessional Education for Improving Workforce Capacity to Treat COPD and Long COVID in Rural Communities”

  • “Shared Decision Making for the Pulmonary Artery Monitoring Device for Patients with Heart Failure”

  • “Implementation of a SmartPhrase for Exercise in the Electronic Health Record for Individuals with Heart Failure”

  • “Implementing a Standardized Workflow for Early Detection of Steroid-Induced Hyperglycemia in Allogeneic Stem Cell Transplant Recipients: A Quality Improvement Project”

  • “Team Science”

  • “Ceramides as Novel Biomarkers of Cardiometabolic Conditions”

  • “Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America”

  • “Heart Failure Epidemiology and Outcomes Statistics, A Report of the Heart Failure Society of America”

  • “Implementation Mapping and Concept Mapping to Explore Guideline Implementation in the Heart Failure Clinic”

  • “Coordinating Resources for a Hybrid Effectiveness and Implementation Trial Across an Integrated Digital Network for Heart Failure”

  • “Creating a Standardized Approach to Program Evaluation in a Magnet Recognized Pediatric Hospital System”

 

 

 

Sedigheh Gharbi | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Sedigheh Gharbi | Stem Cell Research | Best Researcher Award

Dr. Sedigheh Gharbi | Shahid Bahonar University of Kerman, Kerman, Iran | Iran

Assistant Prof. Dr. Sedigheh Gharbi is a dedicated Iranian biologist. She is currently an Assistant Professor at Shahid Bahonar University of Kerman, specializing in molecular biology with a strong focus on non-coding RNAs and their roles in cancer and cardiac regeneration. With over a decade of academic and research experience, Dr. Gharbi has contributed extensively to understanding microRNAs and long non-coding RNAs in disease mechanisms. She is recognized for her work on cardiomyocyte regeneration, cancer biology, and novel RNA regulatory networks. Dr. Gharbi has published numerous peer-reviewed articles, demonstrating her commitment to advancing biomedical research. Her research aims to translate molecular findings into potential therapeutic strategies, especially in oncology and regenerative medicine. She is also known for mentoring students and collaborating internationally to foster innovation in life sciences.

Publication Profile: 

Google Scholar

Education:

Dr. Sedigheh Gharbi completed her PhD in Molecular Biology at Tarbiat Modares University, Tehran. Her doctoral thesis focused on the microRNA expression profile alterations in serum and urine of sulfur mustard victims, under the supervision of Prof. Seyyed Javad Mowla. This work laid the foundation for her expertise in microRNAs and their diagnostic potential in toxicology and disease. Before her PhD, she earned a Master of Science degree from the University of Isfahan, where she conducted research on the mutational screening of the PIK3CA gene in breast cancer patients under Prof. Manoochehr Tavassoli. This early work sparked her interest in cancer genetics and molecular markers. Her education combined advanced molecular techniques with applied biomedical research, equipping her with the skills necessary for innovative studies in RNA biology and its implications in human diseases.

Experienc:

Since 2014, Dr. Gharbi has served as an Assistant Professor at Shahid Bahonar University of Kerman, where she lectures and leads research in molecular biology and cancer genetics. Her academic career is marked by active involvement in teaching, supervising graduate students, and securing research projects. She has a proven record in managing interdisciplinary studies focused on cardiomyocyte regeneration and RNA biology. Dr. Gharbi’s research experience spans molecular profiling of cancer biomarkers, non-coding RNA regulatory networks, and nanotechnology applications in drug delivery. She has collaborated with multiple research teams nationally and internationally, contributing to both fundamental science and translational medicine. Her role involves experimental design, bioinformatics analysis, and dissemination of findings through scientific publications and conferences. Dr. Gharbi’s experience in mentoring young scientists and publishing extensively positions her as a leader in her field.

Research Focus:

Dr. Gharbi’s primary research focus lies in the regulatory roles of non-coding RNAs—especially microRNAs (miRNAs) and long non-coding RNAs (lncRNAs)—in disease pathogenesis and therapy. She investigates cardiomyocyte regeneration by exploring how lncRNAs influence cell cycle progression, aiming to improve heart repair after injury. In oncology, her research centers on the regulatory structure of E-cadherin and the involvement of non-coding RNAs in cancer progression and management. Additionally, Dr. Gharbi is dedicated to identifying novel miRNAs and elucidating their functions in cellular processes like apoptosis and proliferation. Her work integrates molecular biology techniques with bioinformatics to uncover RNA-based biomarkers and therapeutic targets. The intersection of nanotechnology and RNA therapeutics is another emerging area in her studies, aiming to optimize cancer treatment delivery systems. Overall, her research contributes to understanding complex gene regulation mechanisms and developing RNA-based precision medicine strategies.

Publications Top Notes: 

  1. Mir-542 As A Potential and Promising Therapeutic Target For HPV-Positive Cervical Cancers

  2. CircPAN3/miR-221/PTEN Axis and Apoptosis in Myocardial Infarction: Quercetin’s Regulatory Effects

  3. Controlled cytotoxicity of Ag-GO nanocomposite biosynthesized using black peel pomegranate extract against MCF-7 cell line

  4. Characterization of the first microRNA in human CDH1 that affects cell cycle and apoptosis and indicates breast cancers progression

  5. Curcumin loaded on graphene nanosheets induced cell death in mammospheres from MCF-7 and primary breast tumor cells

  6. Bioinformatics Prediction of microRNAs Regulating Epithelial-to-Mesenchymal Transition in Cancer Cells

  7. Secondary toxic effect of graphene oxide and graphene quantum dots alters the expression of miR-21 and miR-29a in human cell lines

  8. Statins: Complex outcomes but increasingly helpful treatment options for patients

  9. Synthesis and characterization of d10 transition metal complexes in bulk and nano scales: DNA binding, molecular docking and anticancer activity against MCF-7 cell line

  10.  Quantification of circulating miR-517c-3p and miR-210-3p levels in preeclampsia

Conclusion:

In conclusion, Assistant Prof. Dr. Sedigheh Gharbi is highly suitable for the Best Researcher Award based on her consistent track record of innovative, impactful research and academic contributions. Her focus on molecular biology, especially the regulatory roles of non-coding RNAs in cancer and cardiac regeneration, addresses some of the most challenging issues in contemporary biomedical science. Her extensive publication record in reputable journals reflects the quality and significance of her work. While there are opportunities for further enhancing her international collaborations, funding portfolio, and translational efforts, her current achievements already mark her as a leading researcher with great potential for continued contributions. Awarding her the Best Researcher Award would recognize her scientific excellence and encourage further advancements in her promising research career.

 

Lin Jin | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Lin Jin | Stem Cell Research | Best Researcher Award

Assist. Prof. Dr. Lin Jin, university of alabama at birmingham, United States

Dr. Lin Jin, PhD, is a leading biomedical scientist specializing in cancer biology and dermatological diseases. Currently affiliated with the Department of Dermatology at the University of Alabama at Birmingham (UAB), Dr. Jin has over 15 years of experience in translational research with a focus on epithelial cell biology, stemness, and inflammation. His research has significantly contributed to the understanding of hidradenitis suppurativa and colorectal cancer. Dr. Jin has held postdoctoral fellowships at both Vanderbilt University and UAB and earned his Ph.D. in Biomedical Engineering from Jinan University, China. As a first and co-corresponding author in several high-impact journals, including PNAS, Nature Communications, and Cancer Research, Dr. Jin is known for his cutting-edge work in molecular mechanisms underlying oncogenesis and inflammatory skin diseases. His dedication to science, paired with strong collaborative leadership, has earned him recognition, including a Best Research Poster award at the Southeastern Consortium for Dermatology in 2023.

Publication Profile:

Google Scholar

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications:
    Dr. Jin has consistently published in top-tier journals including PNAS, Nature Communications, Cancer Research, and Gastroenterology. He has multiple first-author and co-corresponding author credits, which underscores his leadership in research.

  2. Translational Research Excellence:
    His work bridges basic science and clinical application, particularly in hidradenitis suppurativa (HS) and cancer biology, contributing both to understanding molecular mechanisms and developing models for therapeutic screening.

  3. Interdisciplinary Expertise:
    Dr. Jin’s research spans stem cell biology, epigenetics, cancer signaling, and dermatological inflammation, showcasing a rare and valuable interdisciplinary scope.

  4. Award-Winning Research:
    He received the Best Research Poster Award at the 2023 Southeastern Consortium for Dermatology, a competitive and peer-reviewed platform.

  5. Consistent Productivity:
    Over 20 peer-reviewed publications in just over a decade reflect sustained scientific output, with several articles receiving high citation counts.

  6. Academic Mentorship and Collaboration:
    Active involvement in multi-author studies and mentorship roles indicate his collaborative nature and influence in team science.

  7. Recognition by Institution:
    His Nature Communications study was highlighted as a UAB Featured Discovery, which reflects institutional validation of research impact.

⚙️ Areas for Improvement:

  1. Independent PI Track:
    While Dr. Jin has a robust publication record, formal documentation of his role as a Principal Investigator (PI) on grants or independent funding initiatives could further strengthen his candidacy.

  2. Broader Leadership Roles:
    Participation in grant review panels, editorial boards, or leadership within professional societies (e.g., SID committees) would demonstrate a broader academic influence.

  3. Expanded Recognition:
    Additional national or international awards and invited keynote lectures could enhance his external profile and leadership visibility in the field.

🎓 Education:

Dr. Lin Jin’s academic journey reflects a deep commitment to biomedical sciences. He earned his Ph.D. in Biomedical Engineering in 2009 from Jinan University, Guangzhou, China, where he developed expertise in proteomics and molecular biology. Following his doctoral studies, he pursued two consecutive postdoctoral fellowships in Cancer Biology—first at Vanderbilt University (2009–2012), and then at the University of Alabama at Birmingham (2012–2013). These positions enabled him to gain advanced experience in translational research, stem cell biology, and oncogenic signaling pathways. Throughout his education, Dr. Jin focused on the molecular basis of cancer development, particularly exploring signaling pathways and gene regulation. His multidisciplinary training in engineering, biology, and cancer research laid the groundwork for his later success in dermatological research. This diverse academic background has empowered him to lead interdisciplinary projects that bridge basic science and clinical dermatology.

💼 Experience:

Dr. Jin has extensive research experience across prestigious institutions. His career began in China, where he contributed to proteomics and apoptosis research. He then advanced his expertise through postdoctoral roles at Vanderbilt University (2009–2012), working on stemness and epigenetics, and at the University of Alabama at Birmingham (2012–2013), focusing on epithelial biology and inflammation. Since then, he has served as a senior researcher in UAB’s Department of Dermatology, leading numerous projects on hidradenitis suppurativa, colorectal cancer, and stem cell signaling. Dr. Jin has authored over 20 high-impact publications and plays an active role in collaborative research, working with interdisciplinary teams including dermatologists, molecular biologists, and oncologists. His work has directly contributed to therapeutic advancements and better molecular understanding of chronic inflammatory diseases and cancer. As a co-corresponding author and lab leader, he has mentored junior researchers, making him not just a scientist but a key figure in translational medicine.

🏅 Awards and Honors:

Dr. Lin Jin has received notable recognition for his scientific achievements. Most recently, he was honored with the Best Research Poster Award at the 46th Annual Southeastern Consortium for Dermatology in 2023, held in Birmingham, Alabama. This award recognized his pioneering work on epigenetic mechanisms in hidradenitis suppurativa. His work published in Nature Communications was featured as UAB’s Featured Discovery in 2021, underlining the impact of his research in stem cell biology. His contributions have also led to multiple publications in top-tier journals, a testament to his excellence and innovation. Additionally, Dr. Jin has been an active member of the Society for Investigative Dermatology (SID) since 2022, further cementing his role in the dermatological research community. These accolades highlight his consistent drive to advance science and address pressing clinical problems with molecular insight and translational application.

🔬 Research Focus:

Dr. Jin’s research centers around molecular pathogenesis of inflammatory and neoplastic skin diseases, especially hidradenitis suppurativa, a chronic inflammatory condition. His work explores epigenetic regulation, epithelial stem cell dynamics, alternative splicing, and tumorigenesis. His innovative studies use ex vivo models, genomic profiling, and pathway analysis to unravel how dysregulated signaling in epithelial progenitor cells drives both inflammation and hyperproliferation. He has also contributed substantially to understanding cancer stemness and EMT, particularly in colorectal and lung cancers, emphasizing the role of STRAP and Notch/Wnt signaling. Dr. Jin is at the forefront of integrating bioengineering, stem cell biology, and dermatology to discover novel therapeutic strategies. His current projects involve mapping epigenetic switches, developing culture models for drug testing, and identifying biomarkers for skin inflammation and cancer. This integrative and translational approach makes his research highly relevant for both academic advancement and clinical impact.

📚 Publication Top Notes: 

  1. 📘 Epigenetic switch reshapes epithelial progenitor cell signatures and drives inflammatory pathogenesis in hidradenitis suppurativa – PNAS, 2023

  2. 🧬 Mechanism underlying follicular hyperproliferation and oncogenesis in hidradenitis suppurativa – iScience, 2023

  3. 💊 Combined Inhibition of BET Bromodomain and mTORC1/2 Provides Therapeutic Advantage for Rhabdomyosarcoma – Mol Carcinog, 2022

  4. 🧫 Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy – Inflammation, 2022

  5. 🧩 Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling – Semin Cell Dev Biol, 2022

  6. 🧠 STRAP as a mediator of APC mutation-induced intestinal tumorigenesis via a feed-forward mechanism – Gastroenterology, 2021

  7. 🔄 STRAP regulates alternative splicing fidelity during mouse embryonic stem cell lineage commitment – Nat Commun, 2020

  8. 🧪 STRAP deficiency impairs stem cell commitment via retinoic acid dysregulation – Stem Cells, 2018

  9. 🔬 STRAP promotes stemness in colorectal cancer via Notch epigenetic regulation – Cancer Res, 2017

  10. 🧱 TGF-ß-induced Claudin-4 expression via c-Jun signaling in NSCLC – Cell Signal, 2016

📝 Conclusion:

Dr. Lin Jin exemplifies the qualities of an outstanding and impactful researcher. His research has meaningfully advanced the molecular understanding of both inflammatory dermatological disorders and oncogenesis. His strong publication record, interdisciplinary expertise, and recognition within the dermatology and cancer biology communities make him a highly suitable candidate for the Best Researcher Award.

Chun Yan | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Chun Yan | Stem Cell Research | Best Researcher Award

Dr. Chun Yan, Department of Thoracic Surgery, Zhongshan Hospital of Xiamen University, China

Dr. Yan Chun is an Attending Physician at the School of Medicine/Zhongshan Hospital, Xiamen University. With a solid foundation in clinical medicine and surgery, Dr. Chun brings over a decade of experience in thoracic oncology and AI-driven medical research. After earning a Bachelor’s degree from Fujian Medical University, he pursued his Master’s in Surgery at Shanghai Jiao Tong University. Since 2018, Dr. Chun has contributed significantly to clinical practice, medical innovation, and academic research. His current focus includes AI-assisted diagnosis, radiogenomics, and the biomechanics of thoracic surgery. A recognized member of the Minimally Invasive Thoracic Oncology Committee under the Fujian Primary Health Association, he has received multiple accolades for his pioneering work in esophageal cancer therapy. Dr. Chun’s commitment to precision medicine and integration of AI in healthcare highlights his suitability for prestigious research honors and positions him as a leader in translational medical research in China.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation: Dr. Yan Chun holds a Master’s degree in Surgery from Shanghai Jiao Tong University and a Bachelor’s degree in Clinical Medicine, ensuring a robust foundation in both research and clinical practice.

  2. Innovative Research: He leads and participates in cutting-edge projects that integrate AI, radiogenomics, and biomechanical modeling, reflecting a multidisciplinary and forward-thinking approach.

  3. Recognized Excellence: His work has been honored with regional innovation and scientific progress awards, demonstrating tangible contributions to thoracic oncology.

  4. Clinical Expertise: With 7+ years of medical experience, including as an attending physician, he bridges practical medicine with impactful research.

  5. Leadership Role: Serving on a professional committee in minimally invasive thoracic oncology highlights his thought leadership within his specialty.

🧠 Areas for Improvement:

  1. Expanded Publication Record: While impactful, Dr. Chun’s publication portfolio would benefit from a broader presence in international, high-impact journals to boost academic visibility.

  2. International Collaboration: Engaging in cross-border research partnerships could enhance both innovation scope and influence.

  3. Grant Scale: Existing grants are modest in size. Applying for national-level or larger competitive grants could support more ambitious projects.

  4. Mentorship and Training: Documenting roles in mentoring junior researchers or medical students would strengthen his academic leadership profile.

🎓 Education:

Dr. Yan Chun’s academic journey began with a Bachelor of Clinical Medicine (MBBS) from Fujian Medical University (2010–2015), where he gained fundamental clinical knowledge and medical training. He then advanced his specialization in surgery by completing a Master of Surgery (MS) at Shanghai Jiao Tong University (2015–2018), one of China’s top medical institutions. His education emphasized evidence-based clinical practice, surgical skills, and research methodology. During his postgraduate studies, he was actively involved in academic projects, laying a strong foundation for his later research in thoracic oncology and artificial intelligence in medicine. This robust educational background equips him with interdisciplinary expertise, bridging clinical medicine, surgical techniques, and research innovation—especially in radiogenomics and perioperative therapies for esophageal cancer. His training reflects both academic rigor and a forward-looking approach to integrating emerging technologies with healthcare delivery, making him well-prepared to drive impactful research initiatives.

💼 Experience:

Dr. Yan Chun has held progressive roles at Zhongshan Hospital, Xiamen University since 2018. Starting as a Physician (2018–2023), he delivered comprehensive clinical care while engaging in translational research projects. Since July 2023, he has been serving as an Attending Physician, contributing to surgical excellence and AI-assisted diagnostic strategies in thoracic oncology. His hands-on clinical experience is complemented by leadership in grant-funded research, particularly in predictive modeling and biomechanics. Dr. Chun’s involvement in multi-disciplinary teams, collaborations with AI scientists, and contributions to surgical innovation have advanced the care standards in thoracic surgery. He has also actively contributed to institutional and provincial-level scientific programs, showcasing his capability in both practical medicine and medical research. His work stands at the intersection of clinical practice and innovation, and he remains committed to improving outcomes for patients with complex thoracic conditions through precision diagnostics and minimally invasive techniques.

🏅 Awards and Honors:

Dr. Yan Chun has received multiple accolades recognizing his innovative contributions to thoracic oncology and surgical AI. His project, “AI-Assisted Precision Perioperative Individualized Therapy for Esophageal Cancer”, was selected as one of the Top Ten Innovations of the Year by the Xiamen Hospital Association, highlighting its impact on personalized medicine. Another landmark project, “Precision Diagnosis and Treatment Paradigm for Esophageal Squamous Cell Carcinoma Driven by AI and Multi-Omics Integration”, earned him the Third Prize for Scientific and Technological Progress from the Fujian Anti-Cancer Association, underscoring his leadership in advanced cancer care. His awards reflect not only clinical innovation but also excellence in multi-disciplinary research. These honors are a testament to his ability to bridge clinical needs with technological advancements, demonstrating vision, technical skill, and translational impact. They position him as a high-impact researcher contributing meaningfully to China’s evolving healthcare landscape.

🔬 Research Focus:

Dr. Yan Chun’s research is primarily centered on the integration of artificial intelligence, radiogenomics, and thoracic oncology. He leads a government-funded project investigating deep learning-based predictive models for lymph node metastasis and prognosis in esophageal cancer, leveraging imaging-genomics to improve pre- and post-operative decision-making. He also contributed to biomechanical analysis of the NUSS procedure for pectus excavatum, applying finite element modeling to improve surgical outcomes. His work merges clinical data science, image processing, and genomics, aiming to build personalized treatment pathways and enhance minimally invasive approaches. Dr. Chun’s interdisciplinary approach reflects a deep understanding of both computational technologies and real-world clinical challenges. His ambition is to develop AI-powered platforms that augment oncological diagnostics and optimize surgical interventions. Through a combination of hands-on experience and research rigor, he is at the forefront of precision medicine in thoracic surgery, striving for innovation that is both data-driven and patient-centered.

📚 Publications Top Notes:

📖 Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin – Science of the Total Environment, 2024 🌱🫁

🧾 Conclusion:

Dr. Yan Chun demonstrates exceptional promise and maturity as a clinical researcher whose work lies at the confluence of AI, precision medicine, and thoracic surgery. His contributions to the diagnosis and treatment of esophageal cancer through radiogenomic modeling and minimally invasive techniques are both innovative and clinically meaningful. Backed by professional recognition and a strong clinical research ethic, Dr. Chun is a worthy candidate for the Best Researcher Award. With expanded international presence and high-impact publications, he is poised to become a leading figure in the global thoracic oncology research community.

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

Francesco Gaudio | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Francesco Gaudio | Stem Cell Research | Best Researcher Award

Prof. Francesco Gaudio, LUM UNIVERSITY, Italy

Prof. Francesco Gaudio is a highly accomplished hematologist with over 20 years of clinical and academic expertise, specializing in lymphoproliferative neoplasms and hematopoietic stem cell transplantation. Currently serving as Assistant Professor in Hematology at University LUM Giuseppe Degennaro and a practicing medical doctor at “F. Miulli” Hospital, he has previously held long-term roles at renowned Italian hospitals. With a prolific research record, he has authored over 50 publications in high-impact journals and contributed more than 100 abstracts to international conferences. He has conducted research in leading global institutions, including Memorial Sloan-Kettering and Imperial College. Alongside clinical innovation, he is a passionate educator and experienced healthcare manager. His focus on therapeutic advances and multidisciplinary care makes him a leader in hematology research and oncology care.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical and Academic Experience
    Over 20 years of dedicated work in hematology, with expertise in lymphoproliferative disorders and hematopoietic stem cell transplantation.

  2. Robust Research Profile

    • More than 50 peer-reviewed publications in Impact Factor journals.

    • 100+ abstracts presented internationally.

    • Principal and co-investigator in multinational clinical studies.

  3. Global Exposure & Collaborations
    Research training and collaborations at globally recognized centers:

    • Memorial Sloan-Kettering (USA)

    • Imperial College (UK)

    • Lyon Sud (France)

    • VHIO Barcelona (Spain)

  4. Commitment to Academic Growth

    • Teaches Blood Diseases, Oncology, and Pathology.

    • Holds National Scientific Qualification for Associate Professor level.

  5. Leadership & Management Training

    • Managerial courses from SDA Bocconi, ISTUD Foundation, and CURSUS.

  6. Multidisciplinary Impact
    Engages in translational research that bridges hematology, oncology, and emerging areas like cannabinoid therapies and survivorship in cancer.

⚠️ Areas for Improvement:

  1. Leadership in High-Impact Authorship
    While his contribution as co-author is commendable, increasing first or senior authorship in landmark studies would strengthen his research leadership visibility.

  2. Grant Leadership and Funding Acknowledgment
    No mention of competitive grant acquisition or principal leadership in major funded research networks; pursuing this could enhance academic competitiveness.

  3. Public Engagement and Open Science
    Could further boost impact by increasing participation in open-access platforms, public talks, and wider media dissemination of research findings.

🎓 Education:

Prof. Gaudio holds a Degree in Medicine and Surgery from the University of Bari (1995–1996), where he explored clonogenic hematopoietic activity in lymphoma patients. He specialized in Hematology (2001–2002), focusing on stem cell mobilization challenges. He further expanded his scientific foundation with a Postgraduate Specialization in Chemico-Pharmaceutical Research from CARSO (1998). Recognized for academic excellence, he earned the National Scientific Qualification (ASN) for Associate Professor in Hematology, Oncology, and Rheumatology in 2020. His academic path is complemented by top-tier executive and managerial training, including healthcare leadership programs from SDA Bocconi, ISTUD Foundation, and CURSUS. Early education includes a Classical High School Diploma from Liceo Classico ‘Quinto Ennio’, Taranto. His diverse education underscores a balanced mastery of clinical medicine, research, and institutional leadership.

💼 Professional Experience:

Prof. Gaudio’s medical journey spans over two decades in hematology and oncology. Since April 2024, he serves as an Assistant Professor at University LUM Giuseppe Degennaro and practices medicine at “F. Miulli” Regional Hospital. Prior to this, he was a senior hematologist at Policlinico Consorziale, AOU Bari for nearly 19 years, providing expert care and engaging in impactful research. He also worked at Ospedali Riuniti in Foggia, honing his clinical foundations. His experience includes leadership in clinical trials, management of complex hematologic malignancies, and therapeutic protocol development. He is a sought-after speaker, educator, and research collaborator with exposure to international institutions including Sloan-Kettering (USA), Imperial College (UK), and VHIO (Spain). His long-standing service and global outreach reflect deep dedication to patient care, academic excellence, and translational medicine.

🔬 Research Focus:

Prof. Gaudio’s research focuses on lymphomas, leukemias, and hematopoietic stem cell transplantation, combining clinical acumen with molecular innovation. As Principal Investigator in numerous global trials, he has helped shape advanced therapeutic strategies and enhance survival in hematological malignancies. His work delves into mobilization of CD34+ stem cells, radiotherapy-induced toxicity, and biological markers of malignancy. Recent systematic reviews explore epithelial–mesenchymal transcription factors, BPDCN, and the neurological impact of cannabidiol. His interests also span survivorship in Hodgkin lymphoma patients, with emphasis on long-term toxicity and risk evaluation. His teaching integrates updated scientific evidence into medical curricula, training the next generation of hematologists. International collaborations and cross-border research highlight his commitment to innovation and best practices in oncology. Prof. Gaudio’s work not only advances hematology but also bridges clinical gaps through interdisciplinary solutions.

📚 Publications Top Notes:

📄 Exploring the Role of Epithelial–Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review 🔬🧬

📄 Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity 🎗️📊

📄 Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34+ cells in patients with relapsed-refractory diffuse large B-cell lymphomas 🩸💉

📄 The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review 🌿🧠

📄 Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview 🔎🧫

📝 Conclusion:

Prof. Francesco Gaudio is a highly qualified and deserving candidate for the Best Researcher Award. His two decades of contribution to hematology and oncology, combined with a prolific publication record, international collaboration, and dedication to clinical innovation, clearly demonstrate excellence in medical research. While opportunities exist for expanded authorship leadership and grant visibility, his current achievements are deeply impactful and relevant to modern hematologic science. His work bridges bench-to-bedside approaches and continues to benefit both the scientific community and patient outcomes.